24小时热门版块排行榜

返回列表

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

myIDname

木虫 (著名写手)

人民大会堂首席清洁工

SFL-EPI: 17
应助: 143 (高中生)
贵宾: 0.295
金币: 1700.4
散金: 1020
红花: 30
沙发: 2
帖子: 2540
在线: 414.7小时
虫号: 1586017
注册: 2012-01-24
专业: 微/纳机械系统

30 news of the week@SCIENCE 之六：神经学专家卷入内部交易案件

本周第六条报导，原文链接：http://www.sciencemag.org/content/338/6111/1132.1.full.pdf

New York 6

Neurologist Implicated In Insider Trading Case
神经学专家卷入内部交易案件

Federal authorities filed charges last week in what they said is the most lucrative insider trading case in history. According to the Securities and Exchange Commission (SEC), Sidney Gilman, a neurology professor at the University of Michigan, Ann Arbor, fed secret information about clinical trials of an Alzheimer’s drug to Mathew Martoma, a formerportfolio manager at a division of the hedge fund SAC Capital Advisors, allowing Martoma to make more than $276 million inillicit profits and avoid losses with well-timed stock purchases and sales.

联邦政府上周发出了一份指控，里面涉及了到史上涉案金额最高的内部交易。根据安全交易委员会（SEC）提供的信息，Ann Arbor密西根大学的神经学教授Sidney Gilman向Mathew Martoma泄露了Alzheimer公司一种药物的临床试验机密信息，使得这位SCA咨询公司的前任对冲基金部负责人Martoma通过把握买卖股票的有利时机避免了损失，同时获取了超过2.76亿美元的非法收入。

The drug, bapineuzumab, was a oncepromising Alzheimer’s therapy originally developed by Elan and Wyeth. Based on information from Gilman, Martoma allegedly invested more than $700 million in the companies’ stocks when the prospects for bapineuzumab looked good, and later unloaded more than $960 million worth of stock in just over a week when the news turned bad.

Bapineuzumab是Alzheimer公司的治疗药物，最初由Elan和Wyeth研发，并曾被一度看好。根据Gilman交待的情况，Martoma涉嫌在bapineuzumab市场前景光明的时候购买了7亿多美元公司股票，而后仅仅在一个星期之后，当情况逆转的时候又抛出了价值超过9.6亿美元的公司股票。

SEC alleges that Gilman, a former chair of the Michigan neurology department who served as chair of the trial’s Safety and Monitoring Committee, received nearly $108,000 for his consultations with Martoma from a New York–based firm that connects investors with technical experts. Gilman is cooperating with authorities in exchange for nonprosecution.

Gilman之前担任密西根大学神经学系系主任，现在是临床试验安全监管委员会主席。SEC指控他通过纽约一家联系投资人和技术专家的公司，收取了Martoma将近10.8万美元的咨询费。为了免于被起诉，Gilman目前正在配合政府调查。

***************************************************************
Science的原文和本翻译仅用于网友交流学习之用，若您有其它用途，比如商业用途等，请联系Science杂志社了解原文使用权等相关事宜。谢谢！

回复此楼